AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics


AgeX Therapeutics, Inc. (AGE): $0.57

-0.01 (-0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AGE Stock Summary

  • AGE's price/sales ratio is 238.73; that's higher than the P/S ratio of 98.75% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.31 for AgeX Therapeutics Inc; that's greater than it is for only 5.2% of US stocks.
  • As for revenue growth, note that AGE's revenue has grown -92.29% over the past 12 months; that beats the revenue growth of only 0.99% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to AgeX Therapeutics Inc, a group of peers worth examining would be APEN, ONTF, NVVE, LUNG, and TWOU.
  • Visit AGE's SEC page to see the company's official filings. To visit the company's web site, go to www.agexinc.com.

AGE Valuation Summary

  • AGE's EV/EBIT ratio is -5.4; this is 118.43% lower than that of the median Healthcare stock.
  • AGE's EV/EBIT ratio has moved up 8 over the prior 34 months.
  • Over the past 34 months, AGE's price/sales ratio has gone down 31.3.

Below are key valuation metrics over time for AGE.

Stock Date P/S P/B P/E EV/EBIT
AGE 2021-08-31 37.9 -4.7 -4.1 -5.4
AGE 2021-08-30 37.9 -4.7 -4.1 -5.4
AGE 2021-08-27 38.6 -4.8 -4.2 -5.5
AGE 2021-08-26 38.6 -4.8 -4.2 -5.5
AGE 2021-08-25 38.3 -4.8 -4.1 -5.4
AGE 2021-08-24 37.9 -4.7 -4.1 -5.4

AGE Stock Price Chart Interactive Chart >

Price chart for AGE

AGE Price/Volume Stats

Current price $0.57 52-week high $1.64
Prev. close $0.58 52-week low $0.52
Day low $0.56 Volume 46,100
Day high $0.60 Avg. volume 170,050
50-day MA $0.74 Dividend yield N/A
200-day MA $0.79 Market Cap 21.65M

AgeX Therapeutics, Inc. (AGE) Company Bio


AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.


AGE Latest News Stream


Event/Time News Detail
Loading, please wait...

AGE Latest Social Stream


Loading social stream, please wait...

View Full AGE Social Stream

Latest AGE News From Around the Web

Below are the latest news stories about AgeX Therapeutics Inc that investors may wish to consider to help them evaluate AGE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back to a new year, investor!

William White on InvestorPlace | January 3, 2022

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

ALAMEDA, Calif., December 14, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effe

Yahoo | December 14, 2021

AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif., November 30, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. ("ImStem"), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. I

Yahoo | November 30, 2021

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif., November 23, 2021--AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stock

Yahoo | November 23, 2021

Read More 'AGE' Stories Here

AGE Price Returns

1-mo -20.68%
3-mo -39.19%
6-mo -52.50%
1-year N/A
3-year -82.57%
5-year N/A
YTD -47.71%
2021 -28.29%
2020 -16.48%
2019 -39.13%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4139 seconds.